Acumen Pharmaceuticals Inc
ABOS
Company Profile
Business description
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers. The product pipelines include: ALTITUDE-AD; and INTERCEPT-AD.
Contact
1210-1220 Washington Street
Suite 210
NewtonMA02465
USAT: +1 617 344-4190
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
61
Stocks News & Analysis
stocks
Lithium’s latest drop and what it means for ASX investors
Volatility returns to the lithium market.
stocks
Major ASX miner remains overvalued following production update
Iron ore strength keeps production on track despite lower copper output.
stocks
Ahead of earnings, is Alphabet stock a buy, a sell, or fairly valued?
From Google Cloud to Gemini user retention, here’s what we expect from Alphabet’s earnings report.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,974.70 | 32.40 | -0.36% |
| CAC 40 | 8,340.11 | 1.30 | 0.02% |
| DAX 40 | 24,846.69 | 15.71 | 0.06% |
| Dow JONES (US) | 51,839.26 | 307.16 | -0.59% |
| FTSE 100 | 10,524.76 | 75.61 | -0.71% |
| HKSE | 25,143.05 | 580.81 | 2.36% |
| NASDAQ | 25,508.07 | 12.17 | -0.05% |
| Nikkei 225 | 64,141.12 | 2,694.42 | -4.03% |
| NZX 50 Index | 13,683.37 | 12.66 | -0.09% |
| S&P 500 | 7,443.28 | 14.41 | -0.19% |
| S&P/ASX 200 | 8,791.30 | 31.00 | -0.35% |
| SSE Composite Index | 3,796.28 | 32.13 | 0.85% |